Press release
PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024
SEONGNAM, South Korea - PharmaResearch, a leading pharmaceutical/medical device research company, has announced its participation in the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, scheduled from April 5th to 10th in San Diego, California. The company will unveil research findings regarding its groundbreaking anticancer agent, PRD-101, through a poster session.
The presentations will cover diverse topics, including the efficacy demonstrated in various patient-derived xenograft (PDX) animal models and the results of in-depth characterization conducted by the National Cancer Institute's Nanotechnology Characterization Laboratory (NCL).
Presentation Details
Poster Title: Efficient and safe delivery of doxorubicin by DNA fragments: A full preclinical study Date and Time: Tuesday April 9, 1:30 AM - 5:00 PM PT
Session Category: Chemistry
Session Title: Drug Delivery
Session Location: Section 20
Poster Board Number: 3
Abstract number: 5735
About PharmaResearch's PRD-101
PRD-101 represents a significant advancement in cancer treatment, utilizing nucleotide fragments produced through PharmaResearch's proprietary DNA optimization technology (DOTTM) in nano-particle anticancer formulations. Collaborative efforts between PharmaResearch and the University of California Irvine (UCI) researchers, along with support from organizations like the U.S. NCL, have propelled the development of PRD-101. PharmaResearch holds patents and exclusive license associated with PRD-101, marking a milestone in the company's innovative endeavors.
Traditional anticancer drugs often face limitations due to high toxicity, which restricts patient eligibility and necessitates careful dosage management. PharmaResearch anticipates that PRD-101 will address these unmet medical needs in anticancer therapy. The company is committed to advancing quickly into clinical trials based on promising safety and efficacy results obtained from preclinical studies.
About PharmaResearch
PharmaResearch is a pioneering biopharmaceutical company dedicated to enhancing the quality of life for humanity through regenerative medicine. With a diverse portfolio encompassing medicines, medical devices, cosmetics, and supplements, PharmaResearch focuses on leveraging its core ingredients, DOTTM PDRN and DOTTM PN. These active tissue regenerative substances are powered by DOTTM, an exclusive DNA fragments optimization technology safeguarded by a suite of patents. PharmaResearch is located in Seongnam, South Korea, and its US subsidiary, PharmaResarch USA is located in Costa Mesa, Califrornia, US.
PharmaResearch's participation in the AACR Annual Meeting underscores its dedication to pioneering advancements in cancer research and treatment, ultimately aiming to improve patient outcomes and quality of life.
For more information about PharmaResearch and its innovative initiatives, visit http://pharmaresearch.co.kr/en
Media Contact
Company Name: PharmaResearch USA.
Contact Person: Sangjin Choi
Email: Send Email [http://www.universalpressrelease.com/?pr=pharmaresearch-to-present-the-research-on-its-nano-anticancer-drug-prd101-at-the-aacr-annual-meeting-2024]
Country: United States
Website: http://pharmaresearch.co.kr/en/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release PharmaResearch to present the research on its nano anti-cancer drug PRD-101 at the AACR Annual Meeting 2024 here
News-ID: 3444393 • Views: …
More Releases from Getnews
LS Team Launches Post-Typhoon Relief Fund to Support Reconstruction Efforts in t …
Philippines - November 18, 2025 - Following two consecutive and devastating typhoons on November 4 and November 10, the Philippines experienced severe storms, widespread flooding, and extensive damage to homes and infrastructure. In response to this crisis, LS Team swiftly mobilized emergency aid and demonstrated strong corporate social responsibility by launching a dedicated relief and reconstruction initiative to support affected communities.
Immediate Disaster Response and Emergency Aid
Image: https://storage.googleapis.com/mmstudio-images/gallery/w3vsmsTFm0OJ9cBTyypPagPbEzX2/89176099-1763373469-1.jpg
Within hours of the…
Bear and BSPK Partner to Transform Retail Commerce Through Unified Digital and I …
Image: https://www.globalnewslines.com/uploads/2025/11/1763505725.jpg
Strategic Alliance Combines Shopify Expertise with AI-Powered Clienteling Platform
Bear, a leading Shopify-focused digital agency [https://www.beargroup.com] with 18 years of technical expertise, announces a strategic partnership with BSPK, an advanced unified commerce AI platform [https://www.bspk.com/] serving premium and luxury brands. This collaboration creates a powerful synergy between Bear's eCommerce development capabilities and BSPK's sophisticated clienteling technology [https://www.bspk.com/clienteling101], enabling brands to deliver personalized customer experiences across all retail touchpoints.
Partnership Addresses Critical…
Pittsburgh's #1 Home Improvement Company Warns: Gutters Shouldn't Be "Stuffed" T …
Powerhouse Home Improvements warns homeowners that with Pittsburgh's early freeze, clogged gutters can quickly lead to leaks, ice dams, and costly damage. To help prevent holiday headaches, they're offering free safety checks, winter readiness reports, and priority service-reminding everyone that stuffing belongs on your plate, not in your gutters.
Image: https://authoritypresswire.com/wp-content/uploads/2025/11/Untitled-design.png
With Thanksgiving around the corner and National Stuffing Day falling on November 21, Powerhouse Home Improvements-recently named #1 in Pittsburgh-is using…
Oscar Health Contracting 2026 in Alabama and Mississippi Made Simple through FMO …
Hollywood, FL - Oscar Health, Inc. ("Oscar") is expanding its ACA health insurance plans and contracting for agents and brokers for the upcoming 2026 Open Enrollment Period, bringing affordable, tech-driven healthcare options to more individuals and families across Alabama and Mississippi.
This expansion marks a milestone for Oscar as the company continues its mission to make quality healthcare more accessible. The Oscar experience will now reach 573 counties across 20 states…
More Releases for PharmaResearch
Polynucleotides Injectable Overview and Leading Players: Euroresearch S, NeoGene …
The Polynucleotides Injectable market is rapidly gaining traction as a pivotal segment within the aesthetic and medical sectors. Polynucleotides, naturally occurring polymers of nucleotides, have emerged as a revolutionary ingredient in injectables, primarily due to their ability to stimulate tissue regeneration and enhance skin hydration. The relevance of this market is underscored by its applications in various therapeutic and aesthetic procedures, including skin rejuvenation, wrinkle reduction, and overall facial volumization.
𝐘𝐨𝐮…
PharmaResearch Hosts 5th Global Symposium on 'Rejuran'
Over 600 Medical Professionals from 25 Countries Participate, Launch of IRC Committee for Rejuran Global Research Team
Image: https://www.getnews.info/uploads/184db9fd8e5f5bcffadcfd0b82962264.png
Seongnam, South Korea - PharmaResearch (CEO Ki Seock Kang and Thinkyou Kim) announced today that it successfully held the 5th PharmaResearch Global Symposium (PGS) at the Lakai Sandpine Resort on October 28-29, 2024. This year's event attracted approximately 600 aesthetic and medical professionals from 25 countries across Asia, the Americas, Europe, and the…
PharmaResearch Accelerates Global Market Expansion with Investment from Global P …
Accelerating Overseas Expansion and Market Strengthening through CVC Partnership, M&As, and R&D Investments
Image: https://www.getnews.info/uploads/37d3d1ec3a03e85dac6376b2c2e3bb4e.jpg
September 13th, 2024 - PharmaResearch (co-CEOs: Kang Ki Seock, Kim Thinkyou), a leader in aesthetic injectables and regenerative medicines renowned for its flagship skin booster product "Rejuran", announced a significant milestone in its global market expansion efforts, securing KRW 200 billion investment from Europe-based global private equity firm CVC through the issuance of redeemable convertible preferred shares…
PharmaResearch Announces 'Open Innovation Day' Running Until September 30 to Fos …
Anticipating Collaborations with Leading Companies in Aesthetic Medical Devices, Pharmaceuticals and Biotechnology: Application Period August 15 - September 30
Image: https://www.getnews.info/uploads/3276751a42ffba8429fb959e81d25795.jpg
PharmaResearch, a company specializing in regenerative medicine (CEO Kim Thinkyou, Kang Ki-seock), announced that it will host the 'Open Innovation Day'. This initiative aims to foster collaborations in innovative technologies across the aesthetic medical device, pharmaceuticals, biotechnology sectors, both domestically and internationally.
PharmaResearch is seeking partnerships in several key areas, including -…
PharmaResearch Hosts Launch Symposium for REJURAN Registered HB Plus in Singapor …
Sharing information on DOT Trademark patented technology, distinctive efficacy, and safety
Image: https://www.getnews.info/uploads/a9dbc52352e6614785a6dbafd0148817.png
PharmaResearch (CEOs Kang Ki-seok and Kim Thinkyou), a company specializing in regenerative medicine, announced earlier this month that it held a launch symposium for REJURAN Registered HB Plus at Four Seasons Hotel in Singapore.
The symposium aimed to share the technological advancements and clinical experiences of REJURAN Registered HB Plus with local aesthetic experts and medical professionals.
Dr. Michael J. Kim,…
PharmaResearch Presents 'REJURAN Registered ' as a New Solution for Flushing
Effective Use of PN for Flushing... Published in an SCIE-Level Journal
Image: https://www.getnews.info/uploads/52b03d248c2ca7ae3fdd1f69ef67ba5c.png
Flushing refers to the temporary or persistent redness of the skin on the face and neck. It occurs due to vasodilation and is known to arise from various causes, such as hormonal changes, sudden temperature fluctuations, inflammatory skin diseases, and prolonged laser treatments.
While laser and hormone therapies are common treatments for flushing, PharmaResearch(CEO Kim Thinkyou, Kang Ki-seok) has recently…
